Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 148

Dr Keith Pratz - Johns Hopkins University, Baltimore, USA

Dr Keith Pratz speaks to ecancer at ASH 2018 about the phase 1 study into the safety, tolerability and antitumour activity of gilteritinib plus front-line intensive chemotherapy in newly diagnosed AML patients.

He explains that FLT3 is a tyrosene kinase that confers resistance to chemotherapy so adding this new FLT3 inhibitor medicine alongside the standard treatment could improve outcomes.

Dr Pratz reports that they have established a maximum dose for Gilteritinib when combined with chemotherapy and also that the FLT3 mutant group of patients had an above 90% complete remission rate with the combination.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation